Stealth designs to overcome allorejection in engineered cell therapy. Yan-Ruide Li
Trends Immunol. 2026 Mar 11:S1471-4906(26)00039-6. doi: 10.1016/j.it.2026.02.008. Online ahead of print. ABSTRACT The rapid development of allogeneic engineered therapeutic cells has intensified the challenge of host immune-mediated rejection. Advances in molecular immunology, genetic engineering, and induced pluripotent stem cell-based multigene editing have enabled the creation of ‘stealth’ allogeneic cells designed to evade immune detection while … Read more